Strs Ohio Reduces Position in Lantheus Holdings, Inc. $LNTH

Strs Ohio lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 91.2% during the third quarter, HoldingsChannel.com reports. The fund owned 3,900 shares of the medical equipment provider’s stock after selling 40,300 shares during the quarter. Strs Ohio’s holdings in Lantheus were worth $200,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC bought a new position in Lantheus during the second quarter valued at approximately $26,000. First Horizon Corp purchased a new stake in Lantheus during the 3rd quarter valued at $26,000. Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the 2nd quarter valued at $36,000. Tripletail Wealth Management LLC purchased a new position in shares of Lantheus in the 3rd quarter worth $68,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $66.50 on Tuesday. The stock has a 50-day moving average price of $65.07 and a 200 day moving average price of $59.72. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The stock has a market capitalization of $4.41 billion, a P/E ratio of 27.94 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. During the same period last year, the firm posted $1.70 EPS. The company’s revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on LNTH. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Mizuho upped their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Finally, Truist Financial lifted their target price on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.